 The first HIV protease inhibitor, saquinavir, is a peptidomimetic hydroxyethylamine and was marketed in 1995.It is a transition state analogue of a native substrate of the protease.The observation that HIV-1 protease cleaves the sequences containing the dipeptides Tyr-Pro or Phe-Pro was the basic design criterion.